OA pain is the second largest segment of the overall chronic pain market, affecting more than 90 million patients in the G7. The OA pain market represents a lucrative opportunity for drug…
In dry eye disease (DED), the normal functioning of the tear film is disrupted, resulting in troublesome ocular symptoms such as eye burning, and presenting with typical signs such as reduced tear…
Patients with osteoporosis have an increased risk of fractures owing to a loss in bone strength. A significant unmet need exists for treatment that is more effective than current therapies and well…
Chronic idiopathic constipation (CIC) is a common gastrointestinal disorder that is characterized by difficulty defecating, including hard stools and a sensation of incomplete evacuation or…
Post-traumatic stress disorder (PTSD) is a chronic psychiatric condition that noticeably impairs quality of life, although only a limited proportion of newly diagnosed patients seek prescription…
With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues…
Myelofibrosis (MF) is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Ruxolitinib (Jakafi, approved in November 2011) and fedratinib (Inrebic,…
The high number of premium-priced non-small-cell lung cancer (NSCLC) therapies and the large number of NSCLC patients have resulted in a significant financial burden for payers. Costs are set to…
Ischemic stroke (IS) is one of the leading causes of death and neurological disability worldwide. Despite the significant burden of IS, recombinant tissue plasminogen activator (rt-PA/alteplase […
Ischemic stroke (IS) is one of the leading causes of death and neurological disability worldwide. Despite the significant burden of IS, recombinant tissue plasminogen activator (rt-PA/alteplase […
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand which drugs to…
Chronic inducible urticaria (CIndU) encompasses various chronic urticaria subtypes caused by specific triggers. CIndU appears to be more resistant than chronic spontaneous urticaria (CSU) to…
Despite the large number of currently marketed antiepileptic drugs (AEDs), important unmet needs remain for new therapies to treat refractory epilepsy and seizure syndromes such as Lennox-Gastaut…
Seven premium-priced therapies (Avastin, Erbitux, Vectibix, Zaltrap, Stivarga, Lonsurf, and Cyramza) and three immune checkpoint inhibitors (Keytruda, Opdivo, and Yervoy) are FDA-approved to treat…
Type 2 diabetes (T2D) is one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Traditional therapies such as biguanides, insulin secretagogues (…